Share migration to unrestricted trading line

TYRATECH, INC.

('TyraTech' or the 'Company')

MIGRATION FROM TYR TO TYRU

TyraTech, Inc. (AIM: TYR), a leading independent novel pesticide company for human, animal and environmental health, is pleased to announce that 38,000 of its Common Shares will be migrated from its restricted 'TYR' trading line to its unrestricted trading line 'TYRU'. Migration and admission to AIM is expected to occur on or about 04 March 2011.

Following admission of these shares, the Company will have a total of 51,837,468 Common Shares admitted to AIM (including 13,741 treasury shares), of which 51,189,955 will continue to trade under the symbol TYR in a restricted manner as permitted by Regulation S of the U.S. Securities Act of 1933 (the 'Securities Act') and 647,513 will trade under the symbol TYRU in an unrestricted manner pursuant to an exemption provided under the US Securities Act. CREST settlement will not be available for trades in TYR shares.

For further information please contact:

Tyratech, Inc.

Alan Reade, Executive Chairman +1 321 409 7731

www.tyratyech.com

Brewin Dolphin

Matthew David / Iain Marlow +44 (0)20 7248 4400

www.brewin.co.uk

About Tyratech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using TyraTech's proprietary technology. TyraTech, which already has products on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech's technology provides TyraTech with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech is actively developing selected proprietary active ingredients which can then be used for various products across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than two billion people worldwide subject to intestinal parasitic infections.